Data / Research funding / California / Novomedix, Inc.
Novomedix, Inc.: 7 NIH awards ($6.8M), fiscal years 2021 to 2026
Novomedix, Inc. in San Diego, CA is funded under 7 NIH awards ($6.8M) in the NIH and NSF award files, read 2026-11-03. NIH fiscal years 2021 to 2025; NSF fiscal years 2022 to 2026.
SpecStream is the live web data engine for teams and agents. It reads the NIH and NSF award files each time the agencies update them, and this page is that reading, joined to the open federal funding opportunities on Grants.gov. Ask for the awards you track by topic, organization or state and new awards arrive in your sheet, CRM, Slack or agent as the agencies publish them.
- UEI
- XQYMHKGDMU75
- State
- California
Awards
7 awards in the window.
| Award | Agency | Institute or division | Fiscal year | Amount in window | Start | End | Principal investigator | Source |
|---|---|---|---|---|---|---|---|---|
| NOVOMEDIX TRANSITION TO PHASE II - THERAPEUTICS SBIR CONTRACTSBIR PHASE II - ENHANCED OVERALL SURVIVAL IN HIGH-RISK PEDIATRIC SOLID TUMORS USING A NOVEL ORAL SMALL MOLECULE | NIH | National Cancer Institute | 2025 | $2,977,013 | September 15, 2025 | September 14, 2027 | reporter.nih.gov | |
| Novel small molecules for protection against doxorubicin cardiotoxicity in TNBC | NIH | National Heart, Lung, and Blood Institute | 2022 to 2023 | $1,993,505 | May 16, 2022 | October 31, 2024 | SWINDLEHURST, CATHY A | reporter.nih.gov |
| Definitive (GLP) Toxicity and Toxicology Studies for a Novel Small Molecule for Protection Against Cardiotoxicity in Triple Negative Breast Cancer | NIH | National Heart, Lung, and Blood Institute | 2024 | $500,000 | September 15, 2024 | August 31, 2025 | SWINDLEHURST, CATHY A | reporter.nih.gov |
| Novel Therapy for Protection against Diabetes and its Complications in Ischemic Heart Disease | NIH | National Heart, Lung, and Blood Institute | 2021 | $375,000 | September 1, 2021 | August 31, 2022 | SWINDLEHURST, CATHY A | reporter.nih.gov |
| SBIR CONCEPT AWARD TO NOVOMEDIX- NOVEL SMALL MOLECULES FOR THE TREATMENT OF RHABDOMYOSARCOMA | NIH | National Cancer Institute | 2022 | $355,000 | January 20, 2022 | January 19, 2023 | SWINDLEHURST, CATHY | reporter.nih.gov |
| Arthrofibrosis control using small molecule inhibitors of interleukin-11 | NIH | National Institute of Arthritis and Musculoskeletal and Skin Diseases | 2025 | $314,362 | September 22, 2025 | August 31, 2027 | SWINDLEHURST, CATHY A | reporter.nih.gov |
| Novel oral small molecules for progressive pulmonary fibrosis | NIH | National Heart, Lung, and Blood Institute | 2024 | $306,872 | September 20, 2024 | February 28, 2026 | SWINDLEHURST, CATHY A | reporter.nih.gov |
Funding by fiscal year
| Fiscal year | NIH awards | NIH amount | NSF awards | NSF amount |
|---|---|---|---|---|
| 2025 | 2 | $3,291,375 | 0 | $0 |
| 2024 | 2 | $806,872 | 0 | $0 |
| 2023 | 1 | $930,592 | 0 | $0 |
| 2022 | 2 | $1,417,913 | 0 | $0 |
| 2021 | 1 | $375,000 | 0 | $0 |
Open federal funding opportunities
From Grants.gov: notices that funded awards in this table, and open notices on the same agency and assistance listing.
Topics of its NIH awards
- Prevention
- Cancer
- Biotechnology
- Orphan Drug
- Rare Diseases
- Cardiovascular
- Heart Disease
- Breast Cancer
- Pediatric
- Pediatric Cancer
- Lung
- Pulmonary Fibrosis
Updated November 3, 2026. Read from NIH RePORTER ExPORTER and NSF Award Search. Published by NIH and NSF as U.S. government data. NIH awards are fiscal years 2021 to 2025 (NIH files published to 2026-07-09); NSF awards are fiscal years 2022 to 2026 (NSF files published to 2026-11-02). NIH amounts are the total cost of each fiscal year in the window; NSF amounts are the funds obligated in the window. Organizations are matched on the UEI. Open opportunities come from Grants.gov and match on agency and assistance listing number, and on the notice number NIH prints on an award. Free to reuse with credit to SpecStream under CC BY 4.0. Spot a wrong value? Write to [email protected] with the link to this page.